Where Regeneron Pharmaceuticals Stands With Analysts
Portfolio Pulse from Benzinga Insights
Regeneron Pharmaceuticals (NASDAQ:REGN) has received a mix of bullish and indifferent ratings from analysts in the last quarter. The average 12-month price target for the company, according to 13 analysts, is $887.92, with a high of $1050.00 and a low of $811.00. This average price target has increased by 1.69% over the past month.
June 27, 2023 | 6:01 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Regeneron Pharmaceuticals has received mixed analyst ratings, with an average 12-month price target of $887.92, indicating potential upside.
The mixed analyst ratings suggest uncertainty about the company's future performance. However, the average 12-month price target, which has increased over the past month, indicates that analysts see potential upside for the stock.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100